Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Center for Matrix Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Biochemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA.
Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Center for Matrix Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
J Biol Chem. 2021 Jan-Jun;296:100591. doi: 10.1016/j.jbc.2021.100591. Epub 2021 Mar 26.
Our recent work identified a genetic variant of the α345 hexamer of the collagen IV scaffold that is present in patients with glomerular basement membrane diseases, Goodpasture's disease (GP) and Alport syndrome (AS), and phenocopies of AS in knock-in mice. To understand the context of this "Zurich" variant, an 8-amino acid appendage, we developed a construct of the WT α345 hexamer using the single-chain NC1 trimer technology, which allowed us to solve a crystal structure of this key connection module. The α345 hexamer structure revealed a ring of 12 chloride ions at the trimer-trimer interface, analogous to the collagen α121 hexamer, and the location of the 170 AS variants. The hexamer surface is marked by multiple pores and crevices that are potentially accessible to small molecules. Loop-crevice-loop features constitute bioactive sites, where pathogenic pathways converge that are linked to AS and GP, and, potentially, diabetic nephropathy. In Pedchenko et al., we demonstrate that these sites exhibit conformational plasticity, a dynamic property underlying assembly of bioactive sites and hexamer dysfunction. The α345 hexamer structure is a platform to decipher how variants cause AS and how hypoepitopes can be triggered, causing GP. Furthermore, the bioactive sites, along with the pores and crevices on the hexamer surface, are prospective targets for therapeutic interventions.
我们最近的工作确定了一种存在于肾小球基底膜疾病、Goodpasture 病(GP)和 Alport 综合征(AS)患者以及 AS 敲入小鼠中的 IV 型胶原支架 α345 六聚体的遗传变异。为了了解这种“Zurich”变体的上下文,即一个 8 个氨基酸的附加物,我们使用单链 NC1 三聚体技术开发了 WT α345 六聚体的构建体,这使我们能够解决这个关键连接模块的晶体结构。α345 六聚体结构揭示了三聚体-三聚体界面处的 12 个氯离子环,类似于胶原 α121 六聚体,以及 170 种 AS 变体的位置。六聚体表面标记有多个可能对小分子开放的孔和裂缝。环-裂缝-环特征构成了生物活性位点,其中与 AS 和 GP 相关的致病途径汇聚,并可能与糖尿病肾病相关。在 Pedchenko 等人的研究中,我们证明这些位点表现出构象灵活性,这是生物活性位点组装和六聚体功能障碍的动态特性。α345 六聚体结构是破译变体如何导致 AS 以及如何触发低表位从而导致 GP 的平台。此外,生物活性位点以及六聚体表面上的孔和裂缝,是治疗干预的潜在目标。